Diabetes Therapy to Improve BMI and Lung Function in CF
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
To recruit 150 adult patients with cystic fibrosis related diabetes (CFRD) without fasting
hyperglycemia for a multi-center, twelve month, placebo-controlled intervention trial testing
the ability of insulin or repaglinide to improve body mass index (BMI) and stabilize
pulmonary function in cystic fibrosis (CF).
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics Novo Nordisk A/S